Research progress on immune checkpoint inhibitors for the treatment of adverse reactions related to gastric cancer

VernacularTitle:免疫检查点抑制剂治疗胃癌相关不良反应的研究进展
Author: Yawen CHEN ¹ ; Yunhe GAO ; Zhi QIAO
Author Information

1. 中国人民解放军总医院第一医学中心普通外科医学部，北京　100853
Keywords: Stomach neoplasms; Antineoplastic combined chemotherapy protocols; Immunosuppressive agents; Drug-related side effects and adverse reactions
From: International Journal of Surgery 2024;51(1):54-60
CountryChina
Language:Chinese
Abstract: Traditional chemotherapy is the cornerstone of comprehensive treatment for gastric cancer, but its recurrence and metastasis rates are high, and the overall prognosis is not ideal. The rise of immune checkpoint inhibitors (ICI) has brought new hope to gastric cancer patients and changed the current pattern of comprehensive treatment for gastric cancer. With the increasing use of ICI, immune related adverse reactions (irAEs) such as skin toxicity and gastrointestinal toxicity are becoming increasingly common. Scientific understanding, early diagnosis, and graded management are currently the main strategies for handling irAEs. This article aims to review the mechanisms, clinical manifestations, and prediction, treatment, and management of irAEs after ICI treatment of gastric cancer, in order to enhance the understanding of irAEs among clinical physicians, better manage immunotherapy related adverse reactions, and improve the prognosis and quality of life of patients.